Doravirine

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 300 publications

Structural and Mechanistic Basis of F227C-Mediated Hypersusceptibility to Islatravir in HIV-1 Reverse Transcriptase.

Structural and Mechanistic Basis of F227C-Mediated Hypersusceptibility to Islatravir in HIV-1 Reverse Transcriptase.

Journal: bioRxiv : the preprint server for biology
Published: June 22, 2026

Efficacy and safety of doravirine/lamivudine/tenofovir as initial treatment for people living with HIV in China.

Efficacy and safety of doravirine/lamivudine/tenofovir as initial treatment for people living with HIV in China.

Journal: Antimicrobial agents and chemotherapy
Published: June 04, 2026

Pharmacogenomics of current antiretroviral drugs.

Pharmacogenomics of current antiretroviral drugs.

Journal: Pharmacogenomics
Published: May 12, 2026

Doravirine exposure after pill crushing in a patient living with HIV.

Doravirine exposure after pill crushing in a patient living with HIV.

Journal: Infectious diseases now
Published: April 24, 2026

Comparable efficacy of bictegravir/emtricitabine/tenofovir alafenamide and doravirine/lamivudine/tenofovir disoproxil fumarate in therapy-naive Human Immunodeficiency Virus adults with very high baseline viraemia.

Comparable efficacy of bictegravir/emtricitabine/tenofovir alafenamide and doravirine/lamivudine/tenofovir disoproxil fumarate in therapy-naive Human Immunodeficiency Virus adults with very high baseline viraemia.

Journal: Journal of medical microbiology
Published: April 10, 2026

Drug Resistance in HIV Following First-line ART Failure: Insights from a Cross-sectional Study in India.

Drug Resistance in HIV Following First-line ART Failure: Insights from a Cross-sectional Study in India.

Journal: The Journal of the Association of Physicians of India
Published: March 12, 2026

Real-world effectiveness of doravirine-containing antiretroviral therapy in Chinese adults living with HIV-1: a retrospective study.

Real-world effectiveness of doravirine-containing antiretroviral therapy in Chinese adults living with HIV-1: a retrospective study.

Journal: BMC infectious diseases
Published: March 09, 2026

Drug resistance characteristics of rilpivirine in HIV-1-infected patients before starting antiretroviral therapy in nine provinces of China

Drug resistance characteristics of rilpivirine in HIV-1-infected patients before starting antiretroviral therapy in nine provinces of China

Journal: Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
Published: March 01, 2026

Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial.

Doravirine versus dolutegravir-based regimen in antiretroviral treatment-naive people living with HIV-1 (ANRS0392s ELDORADO): protocol for an international, open-label, randomised, non-inferiority, phase III trial.

Journal: BMJ open
Published: February 05, 2026

Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort.

Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort.

Journal: Open forum infectious diseases
Published: January 20, 2026

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Journal: The lancet. HIV
Published: January 12, 2026

Add-on efficacy of doravirine in PLWHIV with virological failure and low-level viremia.

Add-on efficacy of doravirine in PLWHIV with virological failure and low-level viremia.

Journal: The Journal of antimicrobial chemotherapy
Published: January 12, 2026
Showing 1-12 of 300

Last Updated: 06/30/2026